CytRx Initiates Phase 2 Clinical Trial with Bafetinib in B-cell Chronic Lymphocytic Leukemia

CytRx Initiates Phase 2 Clinical Trial with Bafetinib in B-cell Chronic Lymphocytic Leukemia
LOS ANGELES—-CytRx Corporation , a biopharmaceutical company specializing in oncology, today announced initiation of a Phase 2 proof-of-concept clinical trial to evaluate the preliminary efficacy and safety of its oncology drug candidate bafetinib in patients with high-risk B-cell chronic lymphocytic leukemia .

Read more on Business Wire via Yahoo! Finance

More Meth Drug Addiction Info:

• Bafetinib oral pill for advanced prostate cancer from CytRx | DWS …
• FDA Approves Genzyme Pompe Drug, Vertex Hepatitis C Drug Trial …
• Food and Addiction: Sugar Addiction – Proof of Concept | US Colleges
• Biologics supports treatment, cuts cost for cancer care …
• 5-28-10 Daily Small Cap Market News and Stock Highlights from …
• DiaTech Oncology MiCK Chemotherapy Induced Apoptosis Assay Shows …
• GRPR Did Great. Look at GTF Today
• Histopathology Lymph node–Chronic lymphocytic leukemia – sm
• Penny Stocks to watch today
• Sanofi prostate cancer drug shows 28 pct survival | Stock Market News